Alambic Investment Management L.P. Acquires 22,700 Shares of Bruker (BRKR)

Alambic Investment Management L.P. raised its holdings in shares of Bruker (NASDAQ:BRKR) by 38.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 81,700 shares of the medical research company’s stock after acquiring an additional 22,700 shares during the period. Alambic Investment Management L.P. owned about 0.05% of Bruker worth $2,444,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Swiss National Bank grew its position in Bruker by 1.6% during the fourth quarter. Swiss National Bank now owns 188,800 shares of the medical research company’s stock valued at $6,480,000 after acquiring an additional 2,900 shares during the last quarter. Fuller & Thaler Asset Management Inc. grew its position in Bruker by 39.9% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 271,240 shares of the medical research company’s stock valued at $9,309,000 after acquiring an additional 77,400 shares during the last quarter. California Public Employees Retirement System grew its position in Bruker by 8.9% during the fourth quarter. California Public Employees Retirement System now owns 270,363 shares of the medical research company’s stock valued at $9,279,000 after acquiring an additional 22,147 shares during the last quarter. Deutsche Bank AG grew its position in Bruker by 28.2% during the fourth quarter. Deutsche Bank AG now owns 266,998 shares of the medical research company’s stock valued at $9,161,000 after acquiring an additional 58,708 shares during the last quarter. Finally, UBS Asset Management Americas Inc. grew its position in Bruker by 3.4% during the fourth quarter. UBS Asset Management Americas Inc. now owns 98,571 shares of the medical research company’s stock valued at $3,383,000 after acquiring an additional 3,262 shares during the last quarter. Institutional investors and hedge funds own 65.88% of the company’s stock.

A number of analysts have recently weighed in on the company. BTIG Research set a $42.00 price objective on Bruker and gave the company a “buy” rating in a research note on Sunday, May 6th. Zacks Investment Research lowered Bruker from a “buy” rating to a “hold” rating in a research note on Thursday. Bank of America dropped their price objective on Bruker from $37.00 to $34.00 and set a “neutral” rating for the company in a research note on Friday, May 4th. BidaskClub raised Bruker from a “hold” rating to a “buy” rating in a research note on Friday, April 6th. Finally, Leerink Swann increased their price objective on Bruker from $32.00 to $34.00 and gave the company a “market perform” rating in a research note on Friday, February 9th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $32.91.

Shares of BRKR stock opened at $30.50 on Friday. Bruker has a 52 week low of $29.81 and a 52 week high of $29.96. The firm has a market capitalization of $4.64 billion, a P/E ratio of 25.21, a price-to-earnings-growth ratio of 1.96 and a beta of 1.14. The company has a quick ratio of 1.29, a current ratio of 2.22 and a debt-to-equity ratio of 0.26.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, May 3rd. The medical research company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.02. Bruker had a return on equity of 27.04% and a net margin of 4.63%. The company had revenue of $431.70 million during the quarter, compared to analyst estimates of $419.25 million. During the same quarter last year, the firm posted $0.19 earnings per share. The firm’s revenue was up 12.2% on a year-over-year basis. sell-side analysts anticipate that Bruker will post 1.39 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 22nd. Investors of record on Monday, June 4th will be paid a $0.04 dividend. This represents a $0.16 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date is Friday, June 1st. Bruker’s payout ratio is 13.22%.

Bruker Company Profile

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply